SCHEMBL4673886

SCHEMBL4673886

O=C(C=C(O)c1nn[nH]n1)c1csc(Cc2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.40
NCEH1 Q6PIU2 1/20 0.40
DAO P14920 1/20 0.40
LTB4R Q15722 1/20 0.38
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
PTGER1 P34995 1/20 0.34
MMEL1 Q495T6 1/20 0.33
NFE2L2 Q16236 1/20 0.33
PIN1 Q13526 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675363 0.91 PARP1 (0.35) CES1NCEH1DAOLTB4RERCC5
SCHEMBL4676673 0.90 PTGER4 (0.33) CES1NCEH1DAONFE2L2
SCHEMBL4673198 0.90 CES1 (0.32) CES1NCEH1DAOERCC5FEN1
SCHEMBL4674439 0.90 PTGDR2 (0.33) CES1NCEH1DAOERCC5FEN1
SCHEMBL4672517 0.90 HCAR2 (0.39) CES1NCEH1DAOLTB4RPIN1
SCHEMBL4675485 0.89 XDH (0.38) CES1NCEH1DAOERCC5FEN1
SCHEMBL4673387 0.88 MAPK8 (0.43) ERCC5FEN1PTGDR2
SCHEMBL4680230 0.86 PTGDR2 (0.36) CES1NCEH1DAOERCC5FEN1
SCHEMBL4675527 0.86 PARP1 (0.35) CES1NCEH1DAOERCC5FEN1
SCHEMBL4673824 0.82 DAO (0.40) DAOLTB4RPTGER1NFE2L2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885DAO 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.